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background
 
In preclinical and phase 2 studies, adefovir dipivoxil demonstrated potent activity against
hepatitis B virus (HBV), including lamivudine-resistant strains.
 
methods
 
We randomly assigned 515 patients with chronic hepatitis B who were positive for hep-
atitis B e antigen (HBeAg) to receive 10 mg of adefovir dipivoxil (172 patients), 30 mg
of adefovir dipivoxil (173), or placebo (170) daily for 48 weeks. The primary end point
was histologic improvement in the 10-mg group as compared with the placebo group.
 
results
 
After 48 weeks of treatment, significantly more patients who received 10 mg or 30 mg
of adefovir dipivoxil per day than who received placebo had histologic improvement
(53 percent [P<0.001], 59 percent [P<0.001], and 25 percent, respectively), a reduction
in serum HBV DNA levels (by a median of 3.52 [P<0.001], 4.76 [P<0.001], and 0.55 log
copies per milliliter, respectively), undetectable levels (fewer than 400 copies per millili-
ter) of serum HBV DNA (21 percent [P<0.001], 39 percent [P<0.001], and 0 percent, re-
spectively), normalization of alanine aminotransferase levels (48 percent [P<0.001], 55
percent [P<0.001], and 16 percent, respectively), and HBeAg seroconversion (12 percent
[P=0.049], 14 percent [P=0.01], and 6 percent, respectively). No adefovir-associated
resistance mutations were identified in the HBV DNA polymerase gene. The safety pro-
file of the 10-mg dose of adefovir dipivoxil was similar to that of placebo; however,
there was a higher frequency of adverse events and renal laboratory abnormalities in
the group given 30 mg of adefovir dipivoxil per day.
 
conclusions
 
In patients with HBeAg-positive chronic hepatitis B, 48 weeks of 10 mg or 30 mg of adef-
ovir dipivoxil per day resulted in histologic liver improvement, reduced serum HBV DNA
and alanine aminotransferase levels, and increased the rates of HBeAg seroconversion.
The 10-mg dose has a favorable risk–benefit profile for long-term treatment. No adef-
ovir-associated resistance mutations were identified in the HBV DNA polymerase gene.
abstract
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ore than 350 million people
 
worldwide have chronic hepatitis B virus
(HBV) infection.
 
1
 
 Effective treatments
are required to prevent progression of chronic hep-
atitis B to cirrhosis, hepatocellular carcinoma, and
death. Treatment with interferon alfa requires par-
enteral administration and can cause side effects,
such as influenza-like symptoms, anorexia, and de-
pression, that require an adjustment in the dose or
discontinuation of therapy.
 
2
 
 The risk of progressive
liver damage decreases in patients who have hep-
atitis B e antigen (HBeAg) seroconversion after in-
terferon therapy. Lamivudine suppresses HBV rep-
lication and improves histologic liver findings.
 
3
 
However, lamivudine resistance has been reported
in up to 32 percent of patients after one year of ther-
apy
 
4
 
 and in 66 percent after four years.
 
5
 
 Some pa-
tients with lamivudine resistance have had a severe
exacerbation of hepatitis and progressive liver dis-
ease.
 
6
 
 Therefore, well-tolerated antiviral agents that
provide clinical benefit without inducing resistance
are needed to manage chronic hepatitis B.
Adefovir dipivoxil (Hepsera, Gilead Sciences) is
an oral prodrug of adefovir, an analogue of adeno-
sine monophosphate. The active intracellular me-
tabolite, adefovir diphosphate, inhibits HBV DNA
polymerase at levels much lower than those needed
to inhibit human DNA polymerases. In phase 2
studies, daily doses of 30 mg and 60 mg of adefovir
dipivoxil inhibited HBV replication, reducing serum
HBV DNA by approximately 4 log copies per mil-
liliter after 12 weeks.
 
7
 
 Adefovir dipivoxil has also
been efficacious in patients with lamivudine-resist-
ant HBV.
 
8
 
We elected to evaluate in a double-blind, placebo-
controlled study the effects of 10-mg and 30-mg
doses of adefovir dipivoxil in patients with HBeAg-
positive chronic hepatitis B on the basis of the re-
sults of phase 2 studies, which showed that the an-
tiviral activity of doses greater than or equal to 30 mg
was similar. During the long-term, phase 2 study,
data indicated that the 30-mg dose was associated
with mild, reversible nephrotoxicity after 32 weeks.
Therefore, we amended the primary end point for
this study before the analysis and unblinding, to
compare a 10-mg dose of adefovir dipivoxil with
placebo. We report the 48-week results, but the
study is ongoing and will continue for up to 5 years.
When the study was designed, lamivudine was still
an investigational agent; therefore, placebo was se-
lected as the control.
 
study design
 
From March 1999 to March 2000, patients were re-
cruited from 78 centers in North America, Europe,
Australia, and Southeast Asia and randomly as-
signed in a 1:1:1 ratio to receive 10 mg of adefovir
dipivoxil per day, 30 mg of adefovir dipivoxil per day,
or placebo. The central randomization scheme was
stratified according to seven geographic regions.
Permuted blocks (with a block size of six) were used
in each stratum. The placebo and adefovir dipivoxil
tablets were formulated to be indistinguishable
from one another in appearance and taste.
The study was conducted in compliance with the
Declaration of Helsinki and approved by appropri-
ate local regulatory bodies. All patients provided
written informed consent. Liver biopsy was per-
formed at base line and week 48. Biopsy specimens
obtained within six months before randomization
could be used if they had been obtained more than
six months after the completion of prior hepatitis B
therapy. Patients were evaluated every four weeks.
Clinical data were collected, monitored, and en-
tered into a data base by Quintiles. Laboratory tests
were conducted by Covance. The sponsor held the
data and conducted the statistical analyses, which
were predefined; the academic investigators had full
access to the data and contributed substantially to
the design of the study, the collection of the data, the
analysis and interpretation of the data, and the draft-
ing of the manuscript. All authors approved the fi-
nal draft of the manuscript. 
 
patients
 
Male and female patients 16 to 65 years of age who
had hepatitis B e antigen–positive chronic hepati-
tis B and compensated liver disease were eligible for
the study. Chronic hepatitis B was defined by the
presence of serum hepatitis B surface antigen for at
least six months, a serum HBV DNA level of at least
1 million copies per milliliter (measured with the
Roche Amplicor Monitor polymerase-chain-reac-
tion [PCR] assay), and a serum alanine aminotrans-
ferase level that was 1.2 to 10 times the upper limit
of the normal range. Patients were required to have
a prothrombin time that was no more than one sec-
ond above the normal range, a serum albumin level
of at least 3 g per deciliter, a total bilirubin level of
no more than 2.5 mg per deciliter (43 µmol per li-
ter), a serum creatinine level of no more than 1.5 mg
m methods
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per deciliter (133 µmol per liter), and an adequate
blood count. Women of childbearing potential were
eligible if they had a negative pregnancy test and
were using effective contraception.
Criteria for exclusion included a coexisting seri-
ous medical or psychiatric illness; immune globu-
lin, interferon, or other immune- or cytokine-based
therapies with possible activity against HBV disease
within 6 months before screening; organ or bone
marrow transplantation; recent treatment with
systemic corticosteroids, immunosuppressants, or
chemotherapeutic agents; a serum alpha-fetopro-
tein level of at least 50 ng per milliliter; evidence of
a hepatic mass; liver disease that was not due to hep-
atitis B; prior therapy for more than 12 weeks with
a nucleoside or nucleotide analogue with activity
against HBV; and seropositivity for human immu-
nodeficiency virus or hepatitis C or D virus.
 
end points
 
The primary efficacy end point was histologic im-
provement, defined as a reduction of at least two
points in the Knodell necroinflammatory score with
no concurrent worsening of the Knodell fibrosis
score 48 weeks after base line.
 
9
 
 The liver-biopsy
specimens were evaluated by an independent histo-
pathologist who was unaware of the patients’ treat-
ment assignments or of the timing of liver biopsy.
Ranked assessments of necroinflammatory activity
and fibrosis were also performed (and scored as im-
proved, no change, or worse).
Secondary end points included the change from
base line in serum HBV DNA levels, the proportion
of patients with undetectable levels of HBV DNA,
the effect of treatment on the alanine aminotrans-
ferase level, and the proportion of patients with loss
or seroconversion of HBeAg. Serum HBV DNA lev-
els were measured by the Roche Amplicor HBV
Monitor PCR assay (lower limit of detection, 400
copies per milliliter), and the values were log-trans-
formed with use of a base 10 scale.
 
safety analysis
 
The primary safety analysis included all patients
who received at least one dose of study medication
and all events that occurred during treatment or
within 30 days after the discontinuation of study
drug. The severity of adverse events and laboratory
abnormalities was graded according to the Com-
mon Toxicity Criteria of the National Institute of Al-
lergy and Infectious Diseases.
 
10
 
detection of hbv polymerase mutations
 
All serum samples obtained at base line and week
48 were examined in a blinded fashion. HBV DNA
was isolated and amplified by PCR. The positive and
negative strands of the HBV polymerase gene span-
ning the polymerase–reverse-transcriptase domain
(amino acids 349 to 692) were sequenced. The HBV
sequences of the samples obtained at base line and
week 48 from the same patient were aligned with
the MegAlign program (DNAStar).
 
statistical analysis
 
The study was designed to enroll 166 patients per
group, with 90 percent power to detect an absolute
difference of 20 percent (50 percent vs. 30 percent)
between the group given 10 mg of adefovir dipivoxil
and the placebo group, assuming that 25 percent of
patients would have missing biopsy specimens that
would be considered treatment failures and that
8 percent of patients would have missing base-line
biopsy specimens, on the basis of a two-sided type I
error rate of 0.05. The study had 79 percent power
to detect an absolute difference of 10 percent (16
percent vs. 6 percent) in the rate of seroconversion
between the group given 10 mg of adefovir dipivoxil
and the placebo group, assuming that 10 percent of
patients would have missing values (which were
counted as treatment failures). Patients who re-
ceived at least one dose of study medication were
included in the analyses. Patients with missing or
unassessable base-line liver-biopsy specimens were
prospectively excluded from the primary efficacy
analysis. Patients with missing or unassessable data
at 48 weeks were considered not to have had re-
sponses. The unstratified Cochran–Mantel–Haen-
szel test was used to compare each of the adefovir
dipivoxil groups with the placebo group. All P val-
ues were two-sided. No adjustments were made for
multiple comparisons. All serum HBV DNA results
below the lower limit of detection (less than 400
copies per milliliter) were analyzed as being 400
copies per milliliter. No interim analyses were per-
formed other than safety-data summaries, which
were prepared every six months for a review by the
independent external data-monitoring committee.
 
characteristics of the patients
 
Among the 515 patients who were enrolled, 172
were randomly assigned to receive 10 mg of adef-
results
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ovir dipivoxil per day, 173 to receive 30 mg per day,
and 170 to receive placebo. Four patients took no
study medication (one in the 10-mg group and three
in the placebo group). Of the remaining 511 pa-
tients, base-line biopsy specimens were available for
168 patients in the 10-mg group, 165 in the 30-mg
group, and 161 in the placebo group. There were no
significant differences in demographic or HBV dis-
ease characteristics (Table 1) or previous anti-HBV
treatments among the groups. A total of 123 pa-
tients (24 percent) had received treatment with in-
terferon alfa.
 
histologic response
 
The primary analysis was based on the 329 patients
(97 percent) in the group given 10 mg of adefovir
dipivoxil and the placebo group for whom base-line
liver-biopsy specimens were available. Histologic
improvement was seen in 53 percent of patients in
the group given 10 mg of adefovir dipivoxil, 25 per-
cent of those in the placebo group (P<0.001) (Ta-
ble 2), and 59 percent of those in the group given
30 mg of adefovir dipivoxil (P<0.001). The results
were not changed by the addition of the four pa-
tients who underwent randomization but who did
not take any study medication.
After 48 weeks, patients who received 10 mg of
adefovir dipivoxil per day had a median reduction in
the Knodell necroinflammatory score of two points
and those who received 30 mg per day had a median
reduction of three points, as compared with no
change in the placebo group (P<0.001 for both com-
parisons) (Table 2). On ranked assessment, higher
percentages of patients in the 10-mg group and the
30-mg group than in the placebo group had im-
provements in necroinflammatory activity and fi-
brosis, and a higher percentage of patients in the
placebo group had worsening of necroinflamma-
tory activity and fibrosis (P<0.001 for each com-
parison).
 
virologic response
 
At week 48, serum HBV DNA levels had decreased
by a median of 3.52 log copies per milliliter in the
group given 10 mg of adefovir dipivoxil and 4.76 log
copies per milliliter in the 30-mg group, as com-
pared with 0.55 log copies per milliliter in the pla-
cebo group (P<0.001 for each comparison) (Table 3
and Fig. 1). Twenty-one percent of the patients in the
10-mg group and 39 percent of those in the 30-mg
group had undetectable serum levels of HBV DNA,
as compared with 0 percent of the patients in the
placebo group (P<0.001 for each comparison). Loss
of HBeAg occurred in 24 percent of the patients in
the 10-mg group and 27 percent of those in the
30-mg group, as compared with 11 percent of the
patients in the placebo group (P<0.001 for each
comparison). HBeAg seroconversion occurred in 12
percent of the patients in the 10-mg group and 14
percent of those in the 30-mg group, as compared
 
* ULN denotes upper limit of the normal range, and HBV hepatitis B virus.
 
† Values were log-transformed with use of a base 10 scale.
 
Table 1. Base-Line Characteristics of the Patients.*
Characteristic
Placebo
(N=167)
10 mg of
Adefovir
Dipivoxil
(N=171)
30 mg of
Adefovir
Dipivoxil
(N=173)
 
Age — yr
Mean ±SD
Median
Range
37±11.8
35
16–66
34±11.2
32
16–65
34±10.8
32
17–68
Male sex — no. (%) 119 (71) 130 (76) 129 (75)
Race or ethnic group — no. (%)
White
Black
Asian
Other
60 (36)
3 (2)
101 (60)
3 (2)
60 (35)
8 (5)
102 (60)
1 (1)
64 (37)
5 (3)
101 (58)
3 (2)
Weight — kg
Mean ±SD
Median
Range
70±14.9
70
41–134
72±15.9
71
43–118
69±15.9
67
40–129
Alanine aminotransferase
Mean ±SD — U/liter
Median — U/liter
≤ULN — no. (%)
>ULN — no. (%)
Multiples of ULN
Mean ±SD
Median
139±131
94
3 (2)
164 (98)
3.4±3.1
2.4
139±154
95
3 (2)
168 (98)
3.4±4.0
2.3
124±96
92
4 (2)
169 (98)
3.0±2.3
2.3
HBV DNA — log copies/ml†
Mean ±SD
Median
8.12±0.89
8.33
8.25±0.90
8.40
8.22±0.84
8.34
Total Knodell score
Mean ±SD
Median
Range
9.65±3.45
10.0
1–17
9.01±3.33
9.5
0–17
9.55±3.33
10.0
0–16
Knodell necroinflammatory score
Mean ±SD
Median
Range
7.83±2.89
8.0
1–14
7.37±2.75
7.0
0–14
7.84±2.82
8.0
0–12
Knodell fibrosis score
Mean ±SD
Median
Range
1.83±1.12
1.0
0–4
1.64±1.09
1.0
0–4
1.71±1.06
1.0
0–4
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* Relative risks and P values are for the comparison with the placebo group. CI denotes confidence interval.
† Histologic improvement was defined as a decrease of at least two points in the Knodell necroinflammatory score from 
base line to week 48, with no concurrent worsening of the Knodell fibrosis score. Patients who did not satisfy this defini-
tion were considered not to have histologic improvement. Patients with missing or unassessable data at week 48 were 
considered not to have had histologic improvement in the comparison between each adefovir dipivoxil group and the 
placebo group.
‡ The number of patients is the number with assessable liver-biopsy specimens at base line.
§ Values were adjusted for the seven geographic regions involved in the study (Europe, the United States, Canada, Australia, 
Taiwan, Thailand, and other parts of Asia [Singapore, the Philippines, and Malaysia]).
¶The number of patients is the number with assessable liver-biopsy specimens at base line and week 48.
¿ P values are from the general-association Cochran–Mantel–Haenszel statistic for comparisons of the 10-mg group or 
the 30-mg group with the placebo group. All P values are two-sided at a significance level of 0.05, with no adjustments for 
 
multiple comparisons.
 
Table 2. Histologic Improvement and Changes in Necroinflammatory Activity and Fibrosis from Base Line to Week 48.*
Variable Placebo
10 mg of 
Adefovir Dipivoxil
30 mg of 
Adefovir Dipivoxil
Histologic improvement†
 
No. of patients‡ 161 168 165
Histologic improvement — no. (%) 41 (25) 89 (53) 98 (59)
No improvement — no. (%) 105 (65) 61 (36) 47 (28)
Missing data — no. (%) 14 (9) 16 (10) 16 (10)
Unassessable data — no. (%) 1 (1) 2 (1) 4 (2)
Unstratified relative risk
95% CI
2.1
1.5 to 2.8
2.3
1.7 to 3.1
P value <0.001 <0.001
Stratum-adjusted relative risk
95% CI§
2.1
1.6 to 2.8
2.3
1.7 to 3.1
P value <0.001 <0.001
 
Necroinflammatory activity
 
Knodell score
No. of patients¶
Mean (±SD) change in score
Median change in score
Range of scores
P value¿
146
¡0.16±3.06
0
¡10 to 7
150
¡2.58±3.22
¡2
¡9 to 6
<0.001
145
¡3.17±3.30
¡3
¡9 to 5
<0.001
Ranked assessment
No. of patients¶
Improved — no. (%)
No change — no. (%)
Worse — no. (%)
P value¿
145
59 (41)
37 (26)
49 (34)
150
107 (71)
23 (15)
20 (13)
<0.001
145
112 (77)
18 (12)
15 (10)
<0.001
 
Fibrosis
 
Knodell score
No. of patients¶
Mean (±SD) change in score
Median change in score
Range of scores
P value¿
146
¡0.01±0.86
0
¡3 to 2
150
¡0.18±0.84
0
¡2 to 2
0.061
145
¡0.32±0.80
0
¡2 to 2
0.001
Ranked assessment
No. of patients¶
Improved — no. (%)
No change — no. (%)
Worse — no. (%)
P value¿
145
35 (24)
72 (50)
38 (26)
150
62 (41)
67 (45)
21 (14)
<0.001
145
78 (54)
53 (37)
14 (10)
<0.001
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with 6 percent of the patients in the placebo group
(P=0.049 and P=0.011, respectively).
 
biochemical response
 
Median reductions in serum alanine aminotransfer-
ase levels at week 48 were 51 IU per liter in the 10-
mg group and 54 IU per liter in the 30-mg group, as
compared with 17 IU per liter in the placebo group
(P<0.001 for each comparison) (Table 3). Forty-
eight percent of the patients who received 10 mg of
adefovir dipivoxil per day and 55 percent of those
who received 30 mg per day had normal alanine
aminotransferase values at week 48, as compared
with 16 percent of those who received placebo (P<
0.001 for both comparisons).
 
resistance profile
 
The polymerase–reverse transcriptase domain of
the HBV polymerase gene was sequenced from se-
rum samples obtained at base line and week 48 in
381 patients with detectable serum HBV DNA at
both times. No mutations occurred at higher than
background frequencies (less than 1.6 percent).
Seven different novel substitutions were found at
conserved sites in the HBV polymerase in seven pa-
tients (four of whom received adefovir dipivoxil and
three of whom received placebo). All four of the pa-
tients who received adefovir dipivoxil had signifi-
cant reductions in serum HBV DNA levels at week
48. In vitro phenotypic analyses demonstrated that
viruses containing any of the seven substitutions re-
mained fully susceptible to adefovir.
 
safety
 
Similar percentages of patients in each group dis-
continued the study prematurely: 7 percent of those
given 10 mg of adefovir dipivoxil per day and 8 per-
cent of those given 30 mg per day and those given
placebo. The incidence of severe (grade 3 or 4) clin-
ical adverse events was similar: 10 percent in pa-
tients who received 10 mg of adefovir dipivoxil per
day, 9 percent in those who received 30 mg per day,
and 8 percent in the placebo group. The safety pro-
file of the 10-mg group was similar to that of place-
bo with respect to all reported adverse events except
asthenia (25 percent in the 10-mg group vs. 19 per-
cent in the placebo group) and diarrhea (13 percent
vs. 8 percent) (Table 4). Anorexia (10 percent) and
pharyngitis (40 percent) occurred more frequently
in the 30-mg group. Adverse events leading to the
discontinuation of the study drug occurred in 2 per-
cent of the patients in the 10-mg group, 3 percent of
those in the 30-mg group, and less than 1 percent of
those in the placebo group. These events included
increased alanine aminotransferase or aspartate
aminotransferase levels, weight loss, and rash in the
10-mg group; nausea, abdominal pain, headache,
Fanconi-like syndrome, amblyopia, and myocardial
infarction in the 30-mg group; and nausea in the
placebo group.
There was no significant change in median se-
rum creatinine levels at week 48 in the 10-mg group
 
* HBV denotes hepatitis B virus, and CI confidence interval.
† P values are from the general-association Cochran–Mantel–Haenszel statistic 
for comparisons of each adefovir dipivoxil group with the placebo group. All 
P values are two-sided at a significance level of 0.05, with no adjustments for 
multiple comparisons.
‡ Patients who were positive for hepatitis B e antigen (HBeAg) at base line were 
included in the analysis.
§ Seroconversion was defined as loss of HBeAg and concurrent gain of antibody 
against HBeAg at 48 weeks.
¶Patients with base-line alanine aminotransferase levels that exceeded the up-
 
per limit of the normal range were included in the analysis.
 
Table 3. Virologic and Biochemical Responses at Week 48.*
Variable
Placebo
(N=167)
10 mg
of Adefovir
Dipivoxil
(N=171)
30 mg
of Adefovir
Dipivoxil
(N=173)
Virologic response
 
Change in serum HBV DNA 
— log copies/ml
Mean ±SD
Median
95% CI
P value
¡0.98±1.32
¡0.55
¡1.20 to ¡0.77
¡3.57±1.64
¡3.52
¡3.84 to ¡3.31
<0.001
¡4.45±1.62
¡4.76
¡4.72 to ¡4.19
<0.001
Serum HBV DNA <400 copies/
ml — no. (%)
P value†
0 36 (21)
<0.001
67 (39)
<0.001
HBeAg seroconversion — no./
total no. (%)‡§
P value†
9/161 (6) 20/171 (12)
<0.049
23/165 (14)
<0.011
HBeAg loss — no./total no. 
(%)‡
P value†
17/161 (11) 41/171 (24)
<0.001
44/165 (27)
<0.001
 
Biochemical response
 
Change in serum alanine 
aminotransferase level 
— IU/liter
Mean ±SD
Median
95% CI
P value
¡23.0±140.7
¡17
¡45.9 to ¡0.2
¡92.1±167.2
¡51
¡118.8 to ¡65.3
<0.001
¡74.4±128.4
¡54
¡95.6 to ¡53.3
<0.001
Normalization of alanine 
aminotransferase 
— no./total no. (%)¶
P value†
26/164 (16) 81/168 (48)
<0.001
93/169 (55)
<0.001
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and the placebo group; the 30-mg group had a me-
dian increase of 0.2 mg per deciliter (18 µmol per li-
ter). There were no increases from base line of 0.5
mg per deciliter (44 µmol per liter) or greater in the
serum creatinine level (confirmed by two consecu-
tive laboratory assessments) in the 10-mg group or
the placebo group, but 8 percent of patients in the
30-mg group had such an increase (P<0.001). In all
cases, renal function normalized with a dose reduc-
tion or an interruption of treatment. The maximal
reported serum creatinine level was 1.8 mg per deci-
liter (159 µmol per liter) in a patient in the 30-mg
group. There was a median increase in serum phos-
phorus of 0.1 mg per deciliter (0.03 mmol per liter)
in the 10-mg group and the placebo group and a me-
dian decrease of 0.1 mg per deciliter in the 30-mg
group. There were no confirmed instances of serum
phosphorus levels below 2.0 mg per deciliter (0.65
mmol per liter). The incidence of grade 3 or 4 lab-
oratory abnormalities was similar in the adefovir
dipivoxil and placebo groups, except that aspartate
aminotransferase and alanine aminotransferase lev-
els were higher in the placebo group.
Increases in alanine aminotransferase levels to
more than 10 times the upper limit of the normal
range occurred in 10 percent of patients in the group
given 10 mg of adefovir dipivoxil per day, 8 percent
of those given 30 mg per day, and 19 percent of those
given placebo. Concurrent changes in total bilirubin
levels, serum albumin levels, or the prothrombin
time were not seen in any patient in the 10-mg or
30-mg group. In the placebo group, one patient had
a concurrent increase in the total bilirubin level to
greater than 2.5 mg per deciliter and to at least 1 mg
per deciliter (17.1 µmol per liter) above the base-line
value, and one had a concurrent decrease in the se-
rum albumin level (to less than 3.0 g per liter).
After week 48, all patients were reassigned to
new treatment groups for the second 48 weeks of
the study. All patients in the placebo group received
10 mg of adefovir dipivoxil per day. Patients in the
10-mg group were randomly assigned to receive ei-
ther continued treatment with 10 mg per day or
placebo. All patients in the 30-mg group received
placebo.
An interim analysis of data from the second 48-
week period showed a continued antiviral, serolog-
ic, and biochemical response in patients who con-
tinued to receive 10 mg of adefovir dipivoxil per day
(median duration of additional therapy, 16 weeks).
By week 72, 46 percent of patients had fewer than
400 copies of serum HBV DNA per milliliter, 75 per-
 
Figure 1. Mean Change from Base Line in Serum Levels of Hepatitis B Virus 
(HBV) DNA.
 
I bars are 95 percent confidence intervals. P values are for the comparison 
with placebo.
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Table 4. Adverse Events Reported by at Least 10 Percent of Patients 
in the Group Given 30 mg of Adefovir Dipivoxil per Day.
Adverse Event
Placebo
(N=167)
10 mg of 
Adefovir
Dipivoxil
(N=171)
30 mg of 
Adefovir 
Dipivoxil
(N=173)
 
number of patients (percent)
 
Body as a whole
Headache
Asthenia
Abdominal pain
Flu-like syndrome
Pain
Back pain
37 (22)
32 (19)
32 (19)
31 (19)
21 (13)
11 (7)
43 (25)
42 (25)
31 (18)
28 (16)
19 (11)
11 (6)
45 (26)
45 (26)
38 (22)
32 (18)
13 (8)
17 (10)
Digestive tract
Nausea
Diarrhea
Dyspepsia
Flatulence
Anorexia
23 (14)
13 (8)
14 (8)
10 (6)
9 (5)
17 (10)
23 (13)
15 (9)
13 (8)
6 (4)
31 (18)
25 (14)
19 (11)
18 (10)
18 (10)
Nervous system
Dizziness 13 (8) 9 (5) 18 (10)
Respiratory tract
Pharyngitis
Increased cough
54 (32)
21 (13)
44 (26)
11 (6)
70 (40)
19 (11)
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cent had normalization of alanine aminotransfer-
ase levels, 44 percent had loss of HBeAg, and 23 per-
cent had HBeAg seroconversion. Safety data from
the second 48-week period were similar to those in
the first 48 weeks.
In patients with chronic hepatitis B, 48 weeks of
treatment with adefovir dipivoxil resulted in signif-
icant histologic improvement, reduced serum HBV
DNA levels, and increased normalization of alanine
aminotransferase levels and HBeAg seroconversion,
as compared with placebo. These results are similar
to those in the 52-week pivotal clinical trials of la-
mivudine.
 
3,4
 
 Lai et al. reported significant histolog-
ic improvement in 56 percent of patients after one
year of treatment with lamivudine, although the
development of serum HBV DNA polymerase mu-
tations was associated with increases in alanine
aminotransferase and HBV DNA.
 
3
 
 Dienstag et al.
reported histologic improvement in 52 percent of
patients who received 100 mg of lamivudine per day;
anti-HBeAg antibodies developed in 17 percent, and
32 percent lost serum HBeAg.
 
4
 
The patients in this study were from North Amer-
ica, Europe, Australia, and Southeast Asia; the ma-
jority were Asian. The two pivotal trials of lamivu-
dine included predominantly white patients in the
United States
 
4
 
 or only Chinese patients.
 
3
 
 Several
studies have found regional and ethnic differences
in response to both HBV infection and treatments
for hepatitis B.
 
11
 
 The histologic improvement in our
patients was similar among the geographic regions;
therefore, our results may be more representative
of the global population of patients with chronic
hepatitis B. However, black patients were not well
represented.
The efficacy profile of the 10-mg and 30-mg
doses of adefovir dipivoxil was similar, except for
differences in the magnitude of the decrease in se-
rum HBV DNA levels and the percentage of patients
with undetectable serum HBV DNA levels at 48
weeks. Both doses were well tolerated. However, the
increases in serum creatinine levels in the 30-mg
group limit the long-term use of this dose and in-
stead favor the 10-mg dose. No adefovir-associat-
ed resistance mutations were identified during 48
weeks of treatment, which is consistent with find-
ings from other studies evaluating up to 60 weeks
of treatment.
 
12,13
 
In our study, treatment with 10 mg of adefovir
dipivoxil daily was well tolerated and significantly
improved histologic findings in the liver, reduced
serum HBV DNA levels, normalized alanine amino-
transferase levels, and induced HBeAg loss and ser-
oconversion in a diverse population. The favorable
resistance profile of adefovir dipivoxil during 48
weeks of therapy is an advantage, since many pa-
tients with chronic hepatitis B require long-term
therapy.
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